1-8 of 8
Jillian Simard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang, George Wright, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Svetlana Pack, Cody J Peer, Oluwatobi Arisa, Esther Mena, Maria L. Lindenberg, Ethan Bergvall, Craig A. Portell, Rafic J Farah, Seung Tae Lee, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Anna M Juanitez, Crystal Lu, Allison P. Jacob, Heidi Simmons, William D Figg, Seth M. Steinberg, Elaine S Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 434.
https://doi.org/10.1182/blood-2023-180173
Published: 2023
Journal Articles

Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Jillian Simard, James D Phelan, Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Jagan R. Muppidi, Michail Lionakis, Cody J Peer, Amynah Pradhan, Matthias Holdhoff, Lode J. Swinnen, Kieron Dunleavy, Catherine Lai, Sami Ibrahimi, Michael Glantz, John A Butman, Kim Johnson, Seth M. Steinberg, William Figg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 854.
https://doi.org/10.1182/blood-2023-177994
Published: 2023
Journal Articles

Effect of Isavuconazole on Plasma and CSF Levels of Ibrutinib and Plasma Levels of Liposomal Doxorubicin Among Patients Receiving Teddi-R for CNS Lymphoma

Jillian Simard, Cody Peer, Rahul Lakhotia, Christopher Melani, Amynah Pradhan, Andrea Nicole Lucas, William D. Figg, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2022) 140 (Supplement 1): 8876–8877.
https://doi.org/10.1182/blood-2022-162575
Published: 2022
Journal Articles

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2022) 140 (Supplement 1): 6602–6603.
https://doi.org/10.1182/blood-2022-167950
Published: 2022
Journal Articles

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Rafic J. Farah, Seung Tae Lee, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2022) 140 (Supplement 1): 2289–2291.
https://doi.org/10.1182/blood-2022-167887
Published: 2022
Journal Articles

A Prospective Study of Clonal Evolution in Follicular Lymphoma: Circulating Tumor DNA Correlates with Overall Tumor Burden and Fluctuates over Time without Therapy

Allison Distler, Rahul Lakhotia, James D. Phelan, Stefania Pittaluga, Christopher Melani, Jagan R. Muppidi, Jillian Simard, Amynah Pradhan, Amy Hillsman, Yandan Yang, Theresa Davies-Hill, Arthur L. Shaffer, III, Sarah Evans, Mark A. Ahlman, Allison P. Jacob, Alexander Bagaev, Mark Meerson, Ekaterina Postovalova, Olga Kudryashova, Nikita Kotlov, Nathan H. Fowler, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2021) 138 (Supplement 1): 1328.
https://doi.org/10.1182/blood-2021-151096
Published: 2021
Journal Articles

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

Mark Roschewski, James D. Phelan, Stefania Pittaluga, Christopher Melani, Rahul Lakhotia, Jacob J. Chabon, Jagan R. Muppidi, Kathryn A. Lurain, Jillian Simard, Amynah Pradhan, Amy Hillsman, Madeline Rilko, Seth M. Steinberg, George W. Wright, Da Wei Huang, Yandan Yang, Michail S. Lionakis, Alexander Bagaev, Ekaterina Postovalova, Mark Meerson, Olga Kudryashova, Nikita Kotlov, Nathan H. Fowler, David M. Kurtz, Ash A. Alizadeh, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2021) 138 (Supplement 1): 524.
https://doi.org/10.1182/blood-2021-145228
Published: 2021
Journal Articles

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Jillian Simard, MD, Christopher Melani, MD, Rahul Lakhotia, MD, Michail S. Lionakis, MD ScD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Lydia L. Chou, CRNP, Matthias Holdhoff, MD PhD, Michael Glantz, MD PhD, John A. Butman, MD PhD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-137709
Published: 2020